Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...
Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it “frustrating” that despite the favorable Zantac settlement, robust ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
Teva Pharmaceutical Industries Ltd. ADR 1.52% $19.75B ...
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...
GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback